4.6 Article

Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score

期刊

INTERNATIONAL JOURNAL OF CARDIOLOGY
卷 163, 期 2, 页码 206-211

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2011.10.071

关键词

Heart failure; Comorbidities; Prognosis; Risk models

资金

  1. Fondazione Credito Bergamasco (CREBERG)
  2. Deutsche Forschungsgemeinschaft (DFG) [KFO 196]
  3. BMBF
  4. Kompetenznetzwerk Herzinsuffizienz

向作者/读者索取更多资源

Background: Prognostic stratification in heart failure (HF) is crucial to guide clinical management and treatment decision-making. Currently available models to predict HF outcome have multiple limitations. We developed a simple risk stratification model, based on routinely available clinical information including comorbidities, the Cardiac and Comorbid Conditions HF (3C-HF) Score, to predict all-cause 1-year mortality in HF patients. Methods: We recruited in a cohort study 6274 consecutive HF patients at 24 Cardiology and Internal Medicine Units in Europe. 2016 subjects formed the derivation cohort and 4258 the validation cohort. We entered information on cardiac and comorbid candidate prognostic predictors in a multivariable model to predict 1-year outcome. Results: Median age was 69 years, 35.8% were female, 20.6% had a normal ejection fraction, and 65% had at least one comorbidity. During 5861 person-years follow-up, 12.1% of the patients met the study end-point of all-cause death (n=750) or urgent transplantation (n=9). The variables that contributed to outcome prediction, listed in decreasing discriminating ability, were: New York Heart Association class III-IV, left ventricular ejection fraction <20%, no beta-blocker, no renin-angiotensin system inhibitor, severe valve heart disease, atrial fibrillation, diabetes with micro or macroangiopathy, renal dysfunction, anemia, hypertension and older age. The C statistic for 1-year all-cause mortality was 0.87 for the derivation and 0.82 for the validation cohort. Conclusions: The 3C-HF score, based on easy-to-obtain cardiac and comorbid conditions and applicable to the 1-year time span, represents a simple and valuable tool to improve the prognostic stratification of HF patients in daily practice. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Javed Butler, Gerasimos Filippatos, Tariq Jamal Siddiqi, Martina Brueckmann, Michael Bohm, Vijay K. Chopra, Joao Pedro Ferreira, James L. Januzzi, Sanjay Kaul, Ileana L. Pina, Piotr Ponikowski, Sanjiv J. Shah, Michele Senni, Ola Vedin, Subodh Verma, Barbara Peil, Stuart J. Pocock, Faiez Zannad, Milton Packer, Stefan D. Anker

Summary: This study evaluated the impact of Empagliflozin on health-related quality of life in patients with heart failure and preserved ejection fraction. The results showed that Empagliflozin reduced the risk of major heart failure outcomes and improved health-related quality of life. The effects were consistent across different levels of baseline health status.

CIRCULATION (2022)

Article Cardiac & Cardiovascular Systems

Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect

Savina Nodari, Francesco Fioretti, Francesco Barilla

Summary: Early epidemiologic studies suggested that increasing glucose concentrations lead to higher risks of complications in diabetes. However, recent evidence has shown that aggressive efforts to achieve low HbA1c levels can result in worse clinical outcomes and greater risk of hypoglycaemia. This has led to a paradigm shift in the treatment of diabetes.

HEART FAILURE REVIEWS (2023)

Article Cardiac & Cardiovascular Systems

Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

Kieran F. Docherty, Modele O. Ogunniyi, Inder S. Anand, Akshay S. Desai, Mirta Diez, Jonathan G. Howlett, Jose C. Nicolau, Eileen O'Meara, Subodh Verma, Silvio E. Inzucchi, Lars Kober, Mikhail N. Kosiborod, Daniel Lindholm, Felipe A. Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S. Sabatine, Mikaela Sjostrand, Scott D. Solomon, Anna Maria Langkilde, Pardeep S. Jhund, John J. McMurray

Summary: The study investigated the efficacy and safety of dapagliflozin in Black and White patients with heart failure and found that it had similar benefits in reducing worsening heart failure and cardiovascular death in both racial groups.

JACC-HEART FAILURE (2022)

Article Cardiac & Cardiovascular Systems

Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF

Kieran F. Docherty, Joanne Simpson, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Kober, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Olof Bengtsson, Mikaela Sjostrand, Daniel Lindholm, Anna Maria Langkilde, Scott D. Solomon, John J. McMurray

Summary: The MAGGIC score is positively associated with the relative risk of the primary endpoint. Dapagliflozin treatment provides similar benefits for the primary endpoint across the spectrum of MAGGIC risk score.

JACC-HEART FAILURE (2022)

Article Medicine, General & Internal

Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction

Piotr Gajewski, Marat Fudim, Veraprapas Kittipibul, Zoar J. Engelman, Jan Biegus, Robert Zymlinski, Piotr Ponikowski

Summary: In patients with heart failure, permanent ablation of the right greater splanchnic nerve leads to a significant reduction in intracardiac filling pressures during exercise within 24 hours following the procedure.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Cardiac & Cardiovascular Systems

, MBCHB,a , MBCHB,a , MBCHB, MSC, PHD,a , MBCHB,a , MD,b , MD, DMSC,c , MD,d , MD,e , MD, PHD,f , MD, MPH,g,h , PHLIC,i , PHD,j , PHD,k , MD, PHD,i , MD, PHD,i , MD,h , MDa

Su Ern Yeoh, Kieran F. Docherty, Pardeep S. Jhund, Mark C. Petrie, Silvio E. Inzucchi, Lars Kober, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Olof Bengtsson, David W. Boulton, Peter J. Greasley, Anna Maria Langkilde, Mikaela Sjostrand, Scott D. Solomon, John J. V. McMurray

Summary: Hyponatremia is prognostically important in heart failure patients, but does not modify the benefits of dapagliflozin on heart failure exacerbation and mortality.

JACC-HEART FAILURE (2022)

Article Cardiac & Cardiovascular Systems

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF

Carly Adamson, Lorna M. Cowan, Rudolf A. de Boer, Mirta Diez, Jaroslaw Drozdz, Andre Dukat, Silvio E. Inzucchi, Lars Kober, Mikhail N. Kosiborod, Charlotta E. A. Ljungman, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Daniel Lindholm, Olof Bengtsson, David W. Boulton, Peter J. Greasley, Anna Maria Langkilde, Mikaela Sjostrand, Scott D. Solomon, John J. McMurray, Pardeep S. Jhund

Summary: Abnormal liver tests are common in patients with severe heart failure and are associated with adverse clinical outcomes. This study aimed to investigate the prognostic significance of abnormal liver tests in ambulatory patients with heart failure with reduced ejection fraction (HFrEF), explore any treatment interaction between bilirubin and sodium-glucose cotransporter 2 (SGLT2) inhibitors, and examine change in liver tests with SGLT2 inhibitor treatment.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Review Physiology

The Role of Pharmacological Treatment in the Chemoreflex Modulation

Anna Langner-Hetmanczuk, Stanislaw Tubek, Piotr Niewinski, Piotr Ponikowski

Summary: Peripheral chemoreceptors play a crucial role in sensing hypoxia in mammals and adapting to oxygen-deficient conditions. However, chronic overstimulation of these receptors can lead to the progression of sympathetically-mediated diseases. Therefore, deactivating peripheral chemoreceptors has been proposed as a treatment method for these disorders. This review article provides an overview of the physiological background and current understanding of the effects of commonly prescribed medications on the acute and tonic activities of peripheral chemoreceptors.

FRONTIERS IN PHYSIOLOGY (2022)

Meeting Abstract Cardiac & Cardiovascular Systems

Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial

J. H. Butt, P. Dewan, K. Docherty, S. Inzucchi, P. Ponikowski, F. Martinez, O. Bengtsson, M. Sjostrand, S. D. Solomon, M. Sabatine, M. Kosiborod, A. M. Langkilde, P. S. Jhund, L. Kober, J. J. V. Mcmurray

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Article Medicine, General & Internal

Polypill Strategy in Secondary Cardiovascular Prevention

Jose M. Castellano, Stuart J. Pocock, Deepak L. Bhatt, Antonio J. Quesada, Ruth Owen, Antonio Fernandez-Ortiz, Pedro L. Sanchez, Francisco Marin Ortuno, Jose M. Vazquez Rodriguez, Alexandra Domingo-Fernandez, Inigo Lozano, Maria C. Roncaglioni, Marta Baviera, Andreana Foresta, Luisa Ojeda-Fernandez, Furio Colivicchi, Stefania A. Di Fusco, Wolfram Doehner, Antje Meyer, Francois Schiele, Fiona Ecarnot, Ales Linhart, Jean-Claude Lubanda, Gregory Barczi, Bela Merkely, Piotr Ponikowski, Marta Kasprzak, Juan M. Fernandez Alvira, Vicente Andres, Hector Bueno, Timothy Collier, Frans Van de Werf, Pablo Perel, Moises Rodriguez-Manero, Angeles Alonso Garcia, Marco Proietti, Mikkel M. Schoos, Tabassome Simon, Jose Fernandez Ferro, Nicolas Lopez, Ettore Beghi, Yannick Bejot, David Vivas, Alberto Cordero, Borja Ibanez, Valentin Fuster

Summary: The study showed that taking a polypill containing aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction significantly reduced the risk of major adverse cardiovascular events compared to usual care.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Meeting Abstract Cardiac & Cardiovascular Systems

Outcomes related to hyponatraemia and effects of dapagliflozin: findings from DAPA-HF

S. E. Yeoh, P. Jhund, K. Docherty, M. C. Petrie, S. E. Inzucchi, L. Kober, M. N. Kosiborod, F. A. Martinez, P. Ponikowski, M. S. Sabatine, O. Bengtsson, A. M. Langkilde, M. Sjostrand, S. D. Solomon, J. J. V. Mcmurray

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Correction Cardiac & Cardiovascular Systems

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials (vol 11, pg 2160, 2020)

John R. Teerlink, Rafael Diaz, G. Michael Felker, John J. V. McMurray, Marco Metra, Scott D. Solomon, Kirkwood F. Adams, Inder Anand, Alexandra Arias-Mendoza, Tor Biering-Sorensen, Michael Bohm, Diana Bonderman, John G. F. Cleland, Ramon Corbalan, Maria G. Crespo-Leiro, Ulf Dahlstrom, Luis E. Echeverria Correa, James C. Fang, Gerasimos Filippatos, Candida Fonseca, Eva Goncalvesova, Assen R. Goudev, Jonathan G. Howlett, David E. Lanfear, Mayanna Lund, Peter Macdonald, Vyacheslav Mareev, Shin-ichi Momomura, Eileen O'Meara, Alexander Parkhomenko, Piotr Ponikowski, Felix J. A. Ramires, Pranas Serpytis, Karen Sliwa, Jindrich Spinar, Thomas M. Suter, Janos Tomcsanyi, Hans Vandekerckhove, Dragos Vinereanu, Adriaan A. Voors, Mehmet B. Yilmaz, Faiez Zannad, Lucie Sharpsten, Jason C. Legg, Siddique A. Abbasi, Claire Varin, Fady I. Malik, Christopher E. Kurtz

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Correction Cardiac & Cardiovascular Systems

High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality (vol 23, pg 919, 2021)

Radoslaw Sierpinski, Krystian Josiak, Tomasz Suchocki, Katarzyna Wojtas-Polc, Grzegorz Mazur, Aleksandra Butrym, Piotr Rozentryt, Peter Van der Meer, Josep Comin-Colet, Stephan Von Haehling, Wojciech Kosmala, Monika Przewlocka-Kosmala, Waldemar Banasiak, Jolanta Nowak, Adriaan A. Voors, Stefan D. Anker, John G. F. Cleland, Piotr Ponikowski, Ewa A. Jankowska

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Article Cardiac & Cardiovascular Systems

Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department

Davor Milicic, Binyamin Ben Avraham, Ovidiu Chioncel, Yaron D. Barac, Eva Goncalvesova, Avishai Grupper, Johann Altenberger, Maria Frigeiro, Arsen Ristic, Nicolaas De Jonge, Steven Tsui, Jacob Lavee, Giuseppe Rosano, Marisa Generosa Crespo-Leiro, Andrew J. S. Coats, Petar Seferovic, Frank Ruschitzka, Marco Metra, Stefan Anker, Gerasimos Filippatos, Stamatis Adamopoulos, Miriam Abuhazira, Jeremy Elliston, Israel Gotsman, Righab Hamdan, Yoav Hammer, Tal Hasin, Lorrena Hill, Osnat Itzhaki Ben Zadok, Wilfried Mullens, Sanemn Nalbantgil, Massimo Francesco Piepoli, Piotr Ponikowski, Luciano Potena, Arjang Ruhparwar, Aviv Shaul, Laurens F. Tops, Stephan Winnik, Tiny Jaarsma, Finn Gustafsson, Tuvia Ben Gal

Summary: The advancements in LVAD technology and the shortage of donor hearts have led to an increase in LVAD-supported patients, especially older patients undergoing destination therapy, who are at higher risk for other comorbidities. This article provides definitions and a structured approach for managing LVAD-supported patients presenting with various complications in the emergency department, as well as discussing the challenging issue of declaring death in these patients.

ESC HEART FAILURE (2022)

Article Cardiac & Cardiovascular Systems

Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry

Mateusz Sokolski, Sander Trenson, Justyna M. Sokolska, Domenico D'Amario, Philippe Meyer, Nana K. Poku, Tor Biering-Sorensen, Mats C. Hojbjerg Lassen, Kristoffer G. Skaarup, Eduardo Barge-Caballero, Anne-Catherine Pouleur, Davide Stolfo, Gianfranco Sinagra, Klemens Ablasser, Viktoria Muster, Peter P. Rainer, Markus Wallner, Alessandra Chiodini, Pascal S. Heiniger, Fran Mikulicic, Judith Schwaiger, Stephan Winnik, Huseyin A. Cakmak, Margherita Gaudenzi, Massimo Mapelli, Irene Mattavelli, Matthias Paul, Irina Cabac-Pogorevici, Claire Bouleti, Marzia Lilliu, Chiara Minoia, Jeroen Dauw, Jerome Costa, Ahmet Celik, Nathan Mewton, Carlos E. L. Montenegro, Yuya Matsue, Goran Loncar, Michal Marchel, Aris Bechlioulis, Lampros Michalis, Marcus Dorr, Edgard Prihadi, Felix Schoenrath, Daniel R. Messroghli, Wilfried Mullens, Lars H. Lund, Giuseppe M. C. Rosano, Piotr Ponikowski, Frank Ruschitzka, Andreas J. Flammer

Summary: The study assessed the outcome of hospitalized COVID-19 patients with heart failure (HF) compared to those with other cardiovascular diseases and risk factors. It found that patients with HF had a higher in-hospital mortality rate, and acute HF events during hospitalization were associated with further increased mortality.

ESC HEART FAILURE (2022)

暂无数据